ArticleJournal of medical virology2026
Genomic and Immunological Insights Into Chikungunya Virus Evolution During the 2018 and 2023-24 Outbreaks in Southern India.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genomic and Immunological Insights Into Chikungunya Virus Evolution During the 2018 and 2023-24 Outbreaks in Southern India.Journal of medical virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chikungunya virus (CHIKV) continues to pose a significant public health threat due to recurrent outbreaks driven by antigenic drift, vector adaptation and potential changes in virulence. This study examined the genetic and antigenic characteristics of CHIKV isolates from the 2018 and 2023-24 outbreaks in southern India. Whole-genome sequencing and phylogenetic analysis were performed on outbreak isolates. Structural protein B-cell epitopes were analyzed and mutations associated with vector adaptation and neurovirulence were screened. Serum samples collected in mid-2023 were tested using plaque reduction neutralization test against both outbreak strains. All isolates clustered within the C2.3 clade of the ECSA-IOL genotype and showed close relationship with strains from India, Kenya, Thailand, and Bangladesh. A total of 71 nonstructural and 45 structural mutations were identified relative to the reference strain (S27), with fewer variations in the 2023-24 isolates when compared with 2018 isolates. Adaptive mutations E1:K211E, E2:V264A, and E2:I211T indicated possible dual-vector adaptation. No established neurovirulence mutations were detected. Neutralization and epitope analyzes showed reduced antibody efficacy against 2023-24 isolates. The 2023-24 CHIKV strains remain genetically stable but exhibit adaptive mutations that may enhance transmission and reduce neutralization, highlighting the need for continued genomic and immunological surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.